DiaMedica's Preeclampsia/FGR Expansion and Stroke Catalyst on Track
DiaMedica Therapeutics (DMAC) reported Q2 2026 results on August 11, highlighting continued momentum across its pipeline. The most striking development was the completion of the first cohort (six patients) in the early onset fetal growth restriction (FGR) study, a first-ever exposure of DM199 in this severe population. The company also advanced its preeclampsia strategy, refined its dosing rationale, and reaffirmed that ReMEDy2, its Phase II/III acute ischemic stroke trial, is approaching the prespecified interim analysis. With a cash runway through 2027, DiaMedica appears well-positioned to hit multiple catalysts over the next 12 months.
A Second Women's Health Indication Takes Shape
The FGR cohort completion marks a meaningful expansion of DM199's clinical utility. Early onset FGR is a serious complication with no approved therapies—only early delivery, which carries significant neonatal risks. Management noted that this is "the first time that DM199 has been used in early onset patients" and that the study aims to evaluate multiple endpoints including gestational days and uterine artery dilation. As CEO Rick Pauls put it, “This is important as it expands the clinical use of DM199 into a second serious women's health disorder for which there are no approved therapies.” — Dietrich Pauls, Chief Executive Officer · 2026-08-11 The company plans a key opinion leader event in September to present top-line data from this cohort, which could provide an early signal of efficacy.
Dose Response: The Mid-Dose Sweet Spot
The company also reported data from the completed Part 1a extension cohort in late-onset preeclampsia. The results reinforced the hypothesis that DM199 has a non-linear dose-response curve—the most clinically meaningful effects on blood pressure and uterine artery pulsatility index were seen in the mid-dose range, while higher doses may lead to receptor desensitization.
This has directly informed the dosing strategy for subsequent studies, with selection of the mid-dose range (5-10 microgram/kg) for the FGR and early-onset preeclampsia trials. CEO Rick Pauls explained that going too high triggers receptor desensitization, leading to less vasodilation—a mechanistic insight that also aligns with an issued patent on the nonlinear response. “we run into receptor desensitization. And because of that, we see less of the dilation.” — Dietrich Pauls, Chief Executive Officer · 2026-08-11 This data-driven approach de-risks dose selection for future registrational trials.At the prespecified assessment 5 minutes after completion of the IV infusion, mean systolic blood pressure decreased by 29.1 millimeters of mercury from a baseline of 169.3 millimeters of mercury with a p-value less than 0.001.
ReMEDy2: Interim Analysis Nears
The biggest near-term catalyst remains ReMEDy2, the Phase II/III stroke trial. Enrollment has surpassed 85% of the 200 patients required to trigger the interim efficacy analysis, now expected in Q1 2027. The interim will assess whether a sample size reestimate is warranted (300-728 patients) or whether the study should stop for futility. Management remains blinded but noted that the drug's safety profile could enable broad use in community hospitals, a key differentiator. “We have now surpassed 85% of the enrollment target, and we anticipate the interim analysis readout in the first quarter of 2027.” — Dietrich Pauls, Chief Executive Officer · 2026-08-11 This timeline aligns with prior guidance, though enrollment has been volatile month-to-month, as Rick acknowledged. The company is also preparing for a U.S. IND submission pending completion of a rat PK/PD study expected in September—a step that could unlock U.S. sites for the preeclampsia program.
Financial Runway and R&D Investment
DiaMedica ended Q2 with $43.5 million in cash and short-term investments, enough to fund operations through 2027. R&D expenses grew 41% year-over-year to $8.0 million in Q2, reflecting expansion of the clinical team, manufacturing activities, and the ReMEDy2 global footprint. R&D expenses reached $8M in Q2, a 41% increase versus prior year, driven by higher enrollment, manufacturing, and preclinical work for preeclampsia. The company's burn rate remains manageable, with a cash runway of roughly 5.6 quarters, comfortably covering the ReMEDy2 interim and the planned data readouts from the FGR and preeclampsia programs.
Looking back, the company had previously flagged the need for additional animal toxicology work and a potential backup plan. On the May call, CEO Rick Pauls stated, “We have looked at alternative kind of backup plans in case they want something different.” — Dietrich Pauls, Chief Executive Officer · 2026-05-07 Now that the rat study is underway and the FDA has indicated it may be sufficient, the path to a U.S. IND is clearer. Similarly, the interim analysis timing has been consistently communicated; as Pauls noted in May, “after patient 200 is dosed, there'll be a 90-day window here for the primary endpoint and then another approximately 4 weeks for the interim analysis to occur.” — Dietrich Pauls, Chief Executive Officer · 2026-05-07 That cadence remains on track, though a slight shift from Q4 to early Q1 was acknowledged.
In summary, DiaMedica has delivered a quiet but substantive quarter. The FGR cohort is fully enrolled, dosing is being refined based on rigorous pharmacodynamic data, and the stroke study is approaching its pivotal readout. The company's ability to execute on multiple clinical fronts while maintaining a robust balance sheet makes DMAC a name to watch into 2027.